Skip to main content
BioVaxys Technology Corp. logo

BioVaxys Technology Corp. — Investor Relations & Filings

Ticker · BIOV ISIN · CA09076M2004 LEI · 894500UD22QWRLZYJ229 CSE Professional, scientific and technical activities
Open in API
Filings indexed 436 across all filing types
Latest filing 2022-06-30 Regulatory Filings
Country CA Canada
Listing CSE BIOV

About BioVaxys Technology Corp.

https://biovaxys.com/

BioVaxys Technology Corp. is a clinical-stage biopharmaceutical company specializing in the development and out-licensing of novel immunotherapy assets. The core technology is the proprietary DPX™ platform, a unique lipid-in-oil formulation designed for sustained, targeted immune responses. DPX forces active uptake into immune cells and lymph nodes, avoiding systemic side effects common to conventional delivery methods. The platform is versatile, supporting peptides, proteins, mRNA, and small molecules, and is being applied across oncology, infectious disease, allergy, and autoimmune disorders. The lead clinical asset, Maveropepimut-S (MVP-S), has demonstrated promising Phase 2B results in recurrent ovarian cancer and relapsed/refractory Diffuse Large B-Cell Lymphoma (DLBCL). The company is also integrating Artificial Intelligence to enhance immunotherapeutic discovery.

Recent filings

Filing Released Lang Actions
Interim financial statements/report – English.pdf
Regulatory Filings
2022-06-30 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing a clinical study collaboration and progress in vaccine development by BioVaxys Technology Corp. It discusses scientific and manufacturing process developments, regulatory considerations, and forward-looking statements. There are no financial statements, earnings data, regulatory certifications, or detailed management discussions typical of financial or regulatory filings. The content is primarily a corporate announcement about clinical and manufacturing progress, not a formal financial or regulatory report. Therefore, it does not fit into categories like Annual Report, Interim Report, Earnings Release, or Regulatory Filings. It is best classified as a general Regulatory Filing (RNS) since it is a regulatory announcement that does not fit other specific categories.
2022-06-15 English
Decision Document (Preliminary).pdf
Regulatory Filings Classification · 95% confidence The document is a receipt issued by the British Columbia Securities Commission and Ontario Securities Commission for a Preliminary Short Form Base Shelf Prospectus dated June 7, 2022. It is a regulatory acknowledgment of the filing of a prospectus, not the prospectus itself or a financial report. The document length is short (1063 characters) and it serves as an official regulatory receipt rather than a detailed report or announcement of financial results. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory documents that do not fit other specific categories.
2022-06-08 English
Preliminary short form prospectus – English.PDF
Capital/Financing Update Classification · 100% confidence The document is a preliminary short form base shelf prospectus filed by BioVaxys Technology Corp. It discusses the offering of securities including common shares, warrants, subscription receipts, units, and debt securities. The text includes detailed information about the terms of the securities, the plan of distribution, regulatory compliance, and risk factors. It is a formal prospectus document used for capital raising and securities issuance. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities. The document is not an announcement of a report, nor is it a financial report or regulatory filing. It is a detailed prospectus related to capital raising.
2022-06-08 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a manufacturing phase for a vaccine candidate by BioVaxys Technology Corp. It discusses progress in GMP production, clinical study plans, and collaborations but does not contain any financial statements, detailed financial performance data, or regulatory filings such as annual or quarterly reports. It is a corporate update on product development and manufacturing milestones rather than a financial or regulatory report. The document length is 8825 characters, which is substantial but the content is clearly a news announcement about operational progress. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general corporate announcement that does not fit other specific categories like Annual Report, Interim Report, or Earnings Release.
2022-06-08 English
Qualification certificate.PDF
Regulatory Filings Classification · 100% confidence The document is a certification letter from the CEO of BioVaxys Technology Corp. addressed to Canadian securities regulators. It certifies the company's eligibility to file a short form prospectus under National Instrument 44-101. The document is short (1354 characters) and primarily serves as an officer certification related to a prospectus filing. It does not contain financial statements, detailed financial data, or a report itself. According to the Certification Rule, such documents should be classified as Regulatory Filings (RNS).
2022-06-07 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.